E75.22 Gaucher disease

Name of the Condition

• Gaucher disease (ICD-10 Code: E75.22)

Summary

Gaucher disease is a rare inherited lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase. This deficiency leads to the accumulation of glucocerebroside, a type of lipid, in cells, particularly affecting the liver, spleen, bone marrow, and sometimes the nervous system. The condition is part of a broader group of sphingolipid metabolism disorders and presents with variable clinical manifestations depending on the subtype.

Causes

Gaucher disease results from mutations in the GBA gene, which encodes the glucocerebrosidase enzyme. These mutations impair the enzyme's ability to break down glucocerebroside, leading to its buildup in tissues. Inheritance is typically autosomal recessive, meaning both copies of the gene must be mutated for the condition to manifest.

Risk Factors

• Family history of Gaucher disease or related lysosomal storage disorders.
• Consanguineous relationships, increasing the likelihood of recessive gene mutations.
• Ethnic backgrounds with higher carrier frequencies (e.g., Ashkenazi Jewish populations).

Symptoms

• Enlarged liver and spleen (hepatosplenomegaly).
• Bone pain, fractures, or osteoporosis.
• Fatigue and anemia.
• Easy bruising or bleeding.
• Neurological symptoms (in severe subtypes).

Diagnosis

Diagnosis involves clinical evaluation, laboratory tests to measure glucocerebrosidase activity, and genetic testing to identify GBA mutations. Imaging studies (e.g., MRI) may assess organ involvement, while bone marrow biopsies can detect characteristic lipid-laden cells (Gaucher cells).

Treatment Options

Treatment may include enzyme replacement therapy (ERT) to reduce lipid accumulation, substrate reduction therapy (SRT) to decrease glucocerebroside production, and supportive care for symptoms (e.g., pain management, blood transfusions). Hematopoietic stem cell transplantation is an option for severe cases.

Prognosis and Follow-Up

Prognosis varies by subtype, with type 1 being more manageable and types 2/3 involving progressive neurological decline. Regular monitoring of organ function, bone health, and neurological status is essential. Early intervention can improve outcomes, but lifelong management is typically required.

Complications

• Severe bone disease (e.g., avascular necrosis, fractures).
• Liver or spleen damage.
• Neurological impairment (in types 2/3).
• Increased risk of certain cancers (e.g., multiple myeloma).

Lifestyle & Prevention

• Maintain a balanced diet to support overall health.
• Engage in low-impact exercise to preserve bone strength.
• Avoid activities with high injury risk due to bleeding tendencies.
• Genetic counseling for families with a history of the condition.

When to Seek Professional Help

Seek medical attention for persistent fatigue, unexplained bruising, bone pain, or enlarged organs. Immediate care is needed for severe symptoms like severe bleeding, neurological changes, or acute bone crises.

Tips for Medical Coders

Document the specific subtype (e.g., type 1, 2, or 3) when available, as this may impact coding and clinical management. Ensure accurate coding of associated complications (e.g., bone disease, organ enlargement) and confirm the absence of other sphingolipidoses to avoid misclassification.